Key result
ApoA-I mimetic peptides show therapeutic potential to enhance HDL function against atherosclerosis.
Answers are grounded in this paper and cite their sources.
Reviews 25 years of advances in amphipathic peptide mimetics of apolipoprotein A-I, highlighting their potential to optimize high-density lipoprotein function to combat atherosclerosis.
Certain amphipathic α-helical peptides can functionally mimic many of the properties of full-length apolipoproteins, thereby offering an approach to modulate high-density lipoprotein (HDL) for combating atherosclerosis. In this Perspective, we summarize the key findings and advances over the past 25 years in the development of peptides that mimic apolipoproteins, especially apolipoprotein A-I (apoA-I). This assemblage of information provides a reasonably clear picture of the state of the art in the apolipoprotein mimetic field, an appreciation of the potential for such agents in pharmacotherapy, and a sense of the opportunities for optimizing the functional properties of HDL.
No takes yet. Share an insight, caveat, or question.
Leman et al. (2013) conducted a review in Atherosclerosis. Apolipoprotein A-I mimetic peptides was evaluated. Apolipoprotein A-I mimetic peptides represent a potential pharmacotherapeutic approach to modulate high-density lipoprotein for combating atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: